Q-omics provides the consensus-scored EIF4BP9 profile across patient tissues and cancer cell-line models. EIF4BP9 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, EIF4BP9 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, EIF4BP9 RNA expression shows 7,818 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, and THYM as cancer lineages where EIF4BP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF4BP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF4BP9 survival associations across molecular data types. EIF4BP9 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF4BP9 RNA expression–survival associations across cancer types. High EIF4BP9 expression shows unfavorable associations in OV, DLBC and KIRP, but favorable associations in COAD, UCS and KIRC. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for EIF4BP9 RNA expression.
This table summarizes EIF4BP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for EIF4BP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF4BP9 shows lower tumor expression in BRCA and THCA and higher tumor expression in COAD and PRAD. The COAD box plot shows higher EIF4BP9 RNA expression in tumor versus normal tissue (log2 FC = +0.173, t-test p = .007).
This table shows molecular features associated with EIF4BP9 in patient tissues and cancer cell lines. In patient samples, EIF4BP9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
